Merck Signs a Second Oncology Collaboration with Highlight Therapeutics
Shots:
- The P-II Spotlight 203 study will evaluate the combination of BO-112 (intra-tumoral administration) + Keytruda (pembrolizumab) with CR or PR as its 1EPs. The study will evaluate disease control rates- DoR- PFS- OS- as well as safety- tolerability- and PK of the therapy in ~40 patients
- The collaboration will focus on the evaluation of the combination therapy in patients that have progressed on anti-PD-1-based therapy in refractory advanced MM
- The P-II study of combination therapy in patients with liver metastases from colorectal or gastric/GEJ cancer is currently under progress. Highlight Therapeutics has been dosed it first patient P-IIa study in liver metastasis
Ref: PRNewswire | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com